Aviron's Nasal Flu Vaccine Effective In Children
Aviron's nasally-delivered influenza vaccine is effective at preventingthe flu in healthy young children, according to the results of a study supported by the US National Institute of Allergy and Infectious Diseases.
The live-attenuated vaccine provided 93% protection against influenza in this population; only 1% of 1,070 children who received the vaccine developed culture-confirmed influenza during last year's flu season versus 18% of 532 children the same age who received placebo.
Aviron's share price jumped by 28% to $17.125 on the day of the announcement (July 14), and climbed steadily thereafter to trade in the mid-$20s by the time the Marketletter went to press.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze